CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance

Giovanni D’Arena, Vincenzo De Feo, Giuseppe Pietrantuono, Elisa Seneca, Giovanna Mansueto, Oreste Villani, Francesco La Rocca, Fiorella D’Auria, Teodora Statuto, Luciana Valvano, Francesca Arruga, Silvia Deaglio, Dimitar G. Efremov, Alessandro Sgambato, Luca Laurenti

Research output: Contribution to journalReview articlepeer-review


CD200, a transmembrane type Ia glycoprotein belonging to the immunoglobulin protein superfamily, is broadly expressed on a wide variety of cell types, such as B lymphocytes, a subset of T lymphocytes, dendritic cells, endothelial and neuronal cells. It delivers immunosuppressive signals through its receptor CD200R, which is expressed on monocytes/myeloid cells and T lymphocytes. Moreover, interaction of CD200 with CD200R has also been reported to play a role in the regulation of tumor immunity. Overexpression of CD200 has been reported in chronic lymphocytic leukemia (CLL) and hairy cell leukemia but not in mantle cell lymphoma, thus helping to better discriminate between these different B cell malignancies with different prognosis. In this review, we focus on the role of CD200 expression in the differential diagnosis of mature B-cell neoplasms and on the prognostic significance of CD200 expression in CLL, where conflicting results have been published so far. Of interest, increasing evidences indicate that anti-CD200 treatment might be therapeutically beneficial for treating CD200-expressing malignancies, such as CLL.

Original languageEnglish
Article number584427
JournalFrontiers in Oncology
Publication statusPublished - Nov 26 2020


  • CD200
  • chronic lymphocytic leukemia
  • diagnosis
  • flow cytometry
  • prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance'. Together they form a unique fingerprint.

Cite this